Despite significant advances in the use of surgery, chemotherapy and radiotherapy to treat
squamous cell carcinoma of the head and neck (SCCHN), prognosis has improved little over …

Purpose To determine the phase II dose and objective response rate of erlotinib, a selective
epidermal growth factor receptor tyrosine kinase inhibitor, in combination with cisplatin in …

Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer
worldwide, with 700,000 cases diagnosed per year. 1 Although there have been advances …

Aim: Sorafenib is the first small molecule with significant clinical activity for advanced
hepatocellular carcinoma (HCC). However, intolerable adverse events are sometimes …

Introduction: The majority of patients with locally advanced head and neck squamous cell
carcinoma (HNSCC) will recur. The treatment of patients with recurrent/metastatic (R/M …

PURPOSE: This phase II trial assessed the activity and tolerability of cetuximab (C225,
Erbitux) in combination with carboplatin in patients with relapsed platinum-sensitive ovarian …

Summary Background The randomised phase 3 First-Line Erbitux in Lung Cancer (FLEX)
study showed that the addition of cetuximab to cisplatin and vinorelbine significantly …

The majority of patients with head and neck squamous cell carcinoma (HNSCC) present
with locally advanced disease, which requires site-specific combinations of surgery …

Despite progress in the therapeutic management of patients with squamous cell carcinoma
of the head and neck (SCCHN), the mortality rate of patients presenting with advanced …

The epidermal growth factor receptor (EGFR) inhibitor cetuximab is the only FDA-approved
oncogene-targeting therapy for head and neck squamous cell carcinoma (HNSCC). Despite …